18F-FDG PET对复发性妇科癌症患者管理的影响:一项Meta分析
该Meta分析纳入19项研究共6191例复发性妇科癌症患者,评估18F-FDG PET对管理决策的影响。汇总管理改变率为42.0%(95%CI 34.5%-49.6%;I²=92.9%),宫颈癌、子宫癌和卵巢癌分别为48.5%、34.7%和40.3%。作者认为FDG PET对再分期有显著影响,建议在怀疑复发/转移时进行。
要点
- 19项研究共6191例患者,FDG PET汇总管理改变率为42.0%(95%CI 34.5%-49.6%;I²=92.9%)。
- 亚组分析:宫颈癌48.5%(95%CI 37.8%-59.3%;I²=67.8%),子宫癌34.7%(95%CI 33.4%-36.0%;I²=0%),卵巢癌40.3%(95%CI 26.7%-54.7%;I²=95.2%)。
- 作者认为FDG PET对妇科癌症再分期有显著影响,建议在怀疑复发/转移的主要妇科癌症类型中进行。
核心结论
- FDG PET对妇科癌症患者的再分期有显著影响。
- 这些发现表明,在主要妇科癌症类型(包括宫颈癌、卵巢癌和子宫癌)怀疑复发/转移的病例中,应进行FDG PET。
研究设计与样本
- 系统检索MEDLINE和EMBASE数据库中的英文文献,纳入所有关于PET扫描对复发性妇科癌症患者管理影响的研究。
- 共纳入19项研究,包括6191例患者,计算管理改变比例(FDG PET后管理改变的患者占接受FDG PET患者的百分比)。
- 使用MedCalc统计软件14.12.0版进行数据分析。
主要发现
- FDG PET检测复发/转移的管理改变率范围为9.4%至60.7%,汇总效应为42.0%(95%CI 34.5%-49.6%;I²=92.9%)。
- 宫颈癌的管理改变率为48.5%(95%CI 37.8%-59.3%;I²=67.8%)。
- 子宫癌的管理改变率为34.7%(95%CI 33.4%-36.0%;I²=0%)。
- 卵巢癌的管理改变率为40.3%(95%CI 26.7%-54.7%;I²=95.2%)。
临床怎么用
- 作者认为FDG PET对妇科癌症再分期有显著影响,建议在怀疑复发/转移的主要妇科癌症类型(包括宫颈癌、卵巢癌和子宫癌)中进行FDG PET。
局限性
- 汇总管理改变率异质性高(I²=92.9%)。
- 卵巢癌亚组异质性高(I²=95.2%),宫颈癌亚组异质性中等(I²=67.8%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Gynecological cancer is the most prevalent cancer among women worldwide. We performed a meta-analysis to assess the impact of 18 F-FDG PET on the management of patients with recurrent gynecological cancers, including cervical, uterine, and ovarian cancers. METHODS: We systematically searched MEDLINE and EMBASE databases for English-language publications. All published studies on the impact of PET scans on the management of patients with recurrent gynecological cancers were reviewed. The proportion of management change (%), defined as the percentage of patients whose management changed after FDG PET to those who underwent FDG PET, was calculated. The data from each study were analyzed using MedCalc Statistical Software version 14.12.0 (MedCalc Software, Ostend, Belgium). RESULTS: Nineteen studies including 6191 patients were eligible for inclusion. The impact of FDG PET scan for detecting recurrence/metastasis in patients with gynecologic cancer was evaluated using management change rates, ranging from 9.4% to 60.7% with a pooled effect of 42.0% (95% confidence interval [CI], 34.5%-49.6%; I2 = 92.9%). In the subtype analysis, FDG PET scanning resulted in changes in the management in 48.5% (95% CI, 37.8%-59.3%; I2 = 67.8%) of cervical cancer, 34.7% (95% CI, 33.4%-36.0%; I2 = 0%) of uterine cancer, and 40.3% (95% CI, 26.7%-54.7%; I2 = 95.2%) of ovarian cancer cases. CONCLUSIONS: FDG PET has a significant impact on the restaging of patients with gynecological cancer. These findings suggest that FDG PET should be performed, especially in cases of suspected recurrence/metastasis in the main gynecologic cancer types, including cervical, ovarian, and uterine cancers.
引用
- Pak K, Yoon HJ. Impact of 18 F-FDG PET on the Management in Patients With Recurrent Gynecologic cancer : A Meta-analysis. Clin Nucl Med. 2023. PMID: 37756472. doi:10.1097/RLU.0000000000004839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。